S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
NASDAQ:ETON

Eton Pharmaceuticals Stock Forecast, Price & News

$5.21
+0.02 (+0.39 %)
(As of 10/15/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.16
$5.35
50-Day Range
$4.20
$5.43
52-Week Range
$4.03
$10.30
Volume203,019 shs
Average Volume384,238 shs
Market Capitalization$128.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22
30 days | 90 days | 365 days | Advanced Chart
Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eton Pharmaceuticals logo

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETON
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
$40,000.00
Book Value
$0.65 per share

Profitability

Net Income
$-27.97 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$128.17 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

446th out of 1,361 stocks

Pharmaceutical Preparations Industry

201st out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -












Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

Is Eton Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eton Pharmaceuticals?

Wall Street analysts have given Eton Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eton Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 720,000 shares, a decrease of 41.0% from the September 15th total of 1,220,000 shares. Based on an average daily trading volume, of 360,800 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.6% of the company's shares are short sold.
View Eton Pharmaceuticals' Short Interest
.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Eton Pharmaceuticals
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings data on Sunday, August, 15th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company earned $3.07 million during the quarter, compared to analysts' expectations of $3.83 million.
View Eton Pharmaceuticals' earnings history
.

How has Eton Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ETON stock has increased by 24.0% and is now trading at $5.21.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ETON?

2 brokers have issued 1 year price targets for Eton Pharmaceuticals' stock. Their forecasts range from $11.00 to $14.00. On average, they anticipate Eton Pharmaceuticals' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 139.9% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Sean E. Brynjelsen, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Wilson W. Troutman, Chief Financial Officer, Secretary & Treasurer
  • Scott Grossenbach, Vice President-Sales & Marketing
  • Ingrid Hoos, Senior Vice President-Scientific Affairs
  • Paul Stickler, Senior Vice President-Sales & Marketing

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include CHICAGO TRUST Co NA (0.07%). Company insiders that own Eton Pharmaceuticals stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends for Eton Pharmaceuticals
.

Which major investors are buying Eton Pharmaceuticals stock?

ETON stock was bought by a variety of institutional investors in the last quarter, including CHICAGO TRUST Co NA. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Opaleye Management Inc, and Sean Brynjelsen.
View insider buying and selling activity for Eton Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $5.21.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals has a market capitalization of $128.17 million and generates $40,000.00 in revenue each year. The company earns $-27.97 million in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Eton Pharmaceuticals have?

Eton Pharmaceuticals employs 16 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

Where are Eton Pharmaceuticals' headquarters?

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at (847) 787-7361 or via email at [email protected].


This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.